A new study, coordinated by Drs. hibaut Wolf and Benoît Lhermitte (CHRU de Strasbourg), (Strasbourg University Hospital), has just been published in the journal Acta Neuropathologica Communications.
This work is the result of close collaboration between Strasbourg University Hospital, l’ICANS | Strasbourg Cancer Institute,our team OnKO • 3T led by Sophie Martin and Natacha Entz-Werlé's EN-HOPE SMART4CBT consorttium.
A major diagnostic and prognostic challenge
Gliomas are brain tumors sometimes associated with a mutation in the BRAF gene. In this context, the evaluation of another gene, CDKN2A, plays an essential role in refining the diagnosis and guiding the prognosis. However, its detection remains complex.
A study on a rare cohort
Using a cohort enriched in pleomorphic xanthoastrocytomas, the team compared different detection techniques (immunohistochemistry, FISH, sequencing, methylation analysis, etc.). The results show that some routinely used methods may lack reliability, highlighting the need to carefully select detection tools to improve patient care.
A breakthrough for research and clinical practice
This publication provides new insights into these rare brain tumors and improves diagnostic accuracy.
Congratulations to all the authors !
Wolf, T., Reita, D., Deschuyter, M. et al. Challenging CDKN2A assessment in BRAF-altered gliomas: lessons from a pleomorphic xanthoastrocytoma-enriched cohort. acta neuropathol commun 13, 170 (2025). doi.org/10.1186/s40478-025-02089-7
